v3.26.1
Revenue
6 Months Ended
Jun. 30, 2026
Revenue.  
Revenue

Note 11. Revenue

We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product line:

Three Months Ended

Six Months Ended

June 30,

June 30,

(In thousands)

  ​ ​ ​

2026

2025

2026

2025

Revenue

Lymphedema products

$

73,630

$

65,969

$

135,851

$

116,524

Airway clearance products

12,068

12,936

25,114

23,649

Total

$

85,698

$

78,905

$

160,965

$

140,173

Percentage of total revenue

Lymphedema products

 

86%

 

84%

 

84%

 

83%

Airway clearance products

14%

16%

16%

17%

Total

 

100%

 

100%

 

100%

 

100%

Our revenue by channel, inclusive of sales and rental revenue, for the three and six months ended June 30, 2026 and 2025, are summarized in the following table:

Three Months Ended

Six Months Ended

June 30,

June 30,

(In thousands)

  ​ ​ ​

2026

2025

2026

2025

Private insurers and other payers

$

48,791

$

39,041

$

83,765

$

67,986

Veterans Administration

7,412

7,506

13,615

14,043

Medicare

17,427

19,422

38,471

34,495

Durable medical equipment distributors

12,068

12,936

25,114

23,649

Total

$

85,698

$

78,905

$

160,965

$

140,173

Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component.

The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Condensed Consolidated Balance Sheets. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by third-party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third-party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable.

Rental revenue for each of the three and six months ended June 30, 2026 and 2025, was primarily from private insurers and Medicare. Sales-type lease revenue and the associated cost of revenue for the three and six months ended June 30, 2026 and 2025, was:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands)

2026

2025

2026

2025

Sales-type lease revenue

$

9,209

$

8,374

$

17,510

$

17,173

Cost of sales-type lease revenue

 

2,721

 

2,629

 

5,115

 

4,660

Gross profit

$

6,488

$

5,745

$

12,395

$

12,513